Metabolic therapy in the treatment of ischaemic heart disease: The pharmacology of trimetazidine

Fundamental and Clinical Pharmacology

Volumn 17, Issue 2, 2003, Pages 133-145

  Stanley, William C ^a   Marzilli, Mario ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Angina; Coronary artery disease; Diabetes; Glucose; Lactate; Myocardium

Indexed keywords

PLACEBO; PROPRANOLOL; TRIMETAZIDINE;

CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; ENERGY METABOLISM; ESTERIFICATION; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HEMODYNAMICS; HUMAN; ISCHEMIC HEART DISEASE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW;

ANGINA PECTORIS; CARBOHYDRATE METABOLISM; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENERGY METABOLISM; FATTY ACIDS; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037396373     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00154.x     Document Type: Review

References (90)

1. Budingen T. Uber die Moglichkeit einer Ernahrnngsbehandlung des Herzmuskels dutch Einbringen von Traubenzuckerlosunger in den grober Kreislauf. Dt. Arch. Klin. Med. (1914) 114 534-579.
2. Goulston A. The beneficial effect of ingestion of cane sugar in certain forms of heart disease. Brit. J. Med. (1911) I 615.
3. Sodi-Pallares D., Bisteni A., Medrano G.A., Testelli M.R., DeMicheli A. The polarizing treatment of acute myocardial infarction. Dis. Chest. (1963) 43 424-432.
4. Sodi-Pallares D., Testelli M.R., Fishleder B.L. et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am. J. Cardiol. (1962) 9 166-181.
5. Fath-Ordoubadi F., Beatt K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo-controlled trials. Circulation (1997) 96 1152-1156.
6. Rogers W.J., Stanley A.W., Breinig J.B. et al. Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion. Am. Heart. J. (1976) 92 441-454.
7. Oliver M.F., Opie L.H. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet (1994) 343 155-158.
8. Rowe M.J., Dolder M.A., Kirby B.J., Oliver M.F. Effect of a nicotinic-acid analogue on raised plasma-free-fatty-acids after acute myocardial infarction. Lancet (1973) 2 814-818.
9. Rowe M.J., Neilson J.M.M., Oliver M.F. Control of ventricular arrhythmias during myocardial infarction by antilipolytic treatment using a nicotinic-acid analogue. Lancet (1975) 1 295-300.
10. Russell D.C., Oliver M.F. Effect of antilipolytic therapy on ST segment elevation during myocardial ischaemia in man. British Heart J. (1978) 40 117-123.
11. Burges R.A., Gardiner D.G., Higgins A.J. Protection of the ischemic dog heart by oxfenicine. Life Sci. (1981) 29 1847-1853.
12. Higgins A.J., Morville M., Burges R.A., Gardiner D.G., Page M.G., Blackburn K.J. Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischemia rat heart. Life Sci. (1980) 27 963-970.
13. Higgins A.J., Morville M., Burges R.A., Blackburn K.J. Mechanism of action of oxfenicine on muscle metabolism. Biochem. Biophys. Res. Comm. (1981) 100 291-296.
14. Bergman G., Atkinson L., Metcalfe J., Jackson J., Jewitt D.E. Beneficial effect of enhanced myocardial carbohydrate utilization after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur. Heart J. (1980) I 247-253.
15. Stanley W.C. Partial inhibition of cardiac fatty acid oxidation for the treatment of chronic stable angina. Expert Opin. Invest. Drugs (2002) 11 1-15.
16. Chaitman B.R. for the CARISA Investigators. Improved exercise capacity using a novel pFOX inhibitor as antianginal therapy: results of the Combination Assessment Of Ranolazine In Stable Angina (CARISA). Circulation (2001) 104 1B(abstract).
17. Wolff A. MARISA: monotherapy assessment of ranolazine in stable angina. J. Am. Coll. Cardiol. (2000) 35(Suppl A) 408A (abstract).
18. Opie L. The heart: physiology, from cell to circulation. Lippincott-Raven. Philadelphia, 1998.
19. Balaban R.S., Kantor H.L., Katz L.A., Briggs R.W. Relation between work and phosphate metabolite in the in vivo paced mammalian heart. Science (1986) 232 1121-1123.
20. Liedtke A.J. Alterations in carbohydrate and lipid metabolism in the acutely ischemic heart. Prog. Cardiovasc. Dis. (1981) 23 321-326.
21. Stanley W.C., Lopaschuk G.D., Hall J.L., Mccormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc. Res. (1997) 33 243-257.
22. McNulty P.H., Sinusas A.J., Shi C.Q. Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia. J. Clin. Invest. (1996) 98 62-69.
23. Lewandowski E.D., Kudej R.K., White L.T., O'Donnell J.M., Vatner S.F. Mitochondrial preference for short chain fatty acid oxidation during coronary artery constriction. Circulation (2002) 105 367-372.
24. Parker J.O., Chiong M.A., West R.O., Case R.B. Sequential alterations in myocardial lactate metabolism, S-T segments, and left ventricular function during angina induced by atrial pacing. Circulation (1969) 40 113-131.
25. 13C3] lactate: a new approach for investigating human myocardial metabolism during ischemia. J. Am. Col. Cardiol. (1985) 5 1138-1146.
26. Chandler M.P., Huang H., McElfresh T.A., Stanley W.C. Increased myocardial glycolysis and lactate production despite continued fatty acid uptake during demand-induced ischemia. Am. J. Physiol. (2002) 282 H1871-H1878.
27. Lopaschuk G.D., Belke D.D., Gamble J., Itoi T., Schonekess B.O. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim. Biophys. Acta. (1994) 1213 263-276.
28. Van der Vusse G.J., Van Bilsen M., Glatz J.F. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc. Res. (2000) 45 279-293.
29. 14C-labeled substrates in humans. J. Clin. Invest. (1987) 79 359-366.
30. Kunau W.H., Dommes V., Schulz H. Beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Progr. Lip. Res. (1995) 34 267-342.
31. Schulz H. Regulation of fatty acid oxidation in heart. J. Nutrition (1994) 124 165-171.
32. Gertz E.W., Wisneski J.A., Stanley W.C., Neese R.A. Myocardial substrate utilization during exercise in humans: dual carbon-labeled carbohydrate isotope experiments. J. Clin. Invest. (1988) 82 2017-2025.
33. Wisneski J.A., Gertz E.W., Neese R.A., Gruenke L.D., Morris D.L., Craig J.C. Metabolic fate of extracted glucose in normal human myocardium. J. Clin. Invest. (1985) 76 1819-1827.
34. Wisneski J.A., Stanley W.C., Gertz E.W., Neese R.A. Effects of hyperglycemia on myocardial glycolytic activity in normal humans. J. Clin. Invest. (1990) 85 1648-1656.
35. Randle P.J., Hales C.N., Garland P.B., Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. The Lancet (1963) II 785-789.
36. Randle P.J., Newsholme E.A., Garland P.B. Regulation of glucose uptake by muscle. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem. J. (1964) 93 652-665.
37. Hansford R.G., Cohen L. Relative importance of pyruvate dehydrogenase interconversion and feed-back inhibition in the effect of fatty acids on pyruvate oxidation by rat heart mitochondria. Arch. Biochem. Biophys. (1978) 191 65-81.
38. Wieland O., Funcke H.V., Loffler G. Interconversion of pyruvate dehydrogenase in rat heart muscle upon perfusion with fatty acids or ketone bodies. FEBS Lett. (1971) 15 295-298.
39. Wieland O., Siess E., Schulze-Wethmar F.H., Funcke H.G., Winton B. Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney: effect of diabetes, fasting and refeeding on pyruvate dehydrogenase interconversion. Arch. Biochem. Biophys. (1971) 143 593-601.
40. Schoder H., Knight R.J., Kofoed K.F., Schelbert H.R., Buxton D.B. Regulation of pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic myocardium. Biochim. Biophys. Acta. (1998) 1406 62-72.
41. Stanley W.C., Hernandez L.A., Spires D.A., Bringas J., Wallace S., McCormack J.G. Pyruvate dehydrogenase activity and malonyl CoA levels in normal and ischaemic swine myocardium: effects of dichloroacetate. J. Mol. Cell. Cardiol. (1996) 29 905-914.
42. Crea F., Gaspardone A. New look to an old symptom: angina pectoris. Circulation (1997) 96 3766-3773.
43. Li R.A., Leppo M., Miki T., Seino S., Marbán E. Molecular basis of electrocardiographic ST-segment elevation. Circ. Res. (2000) 87 837-839.
44. Staniforth A.D. Contemporary management of chronic stable angina. Drugs & Aging (2001) 18 109-21.
45. Fabiato A., Fabiato F. Effects of pH on the myofilaments and the sarcoplasmic reticulum of skinned cells from cardiac and skeletal muscles. J. Physiol. (London) (1978) 276 233-255.
46. Murphy E., Perlman M., London R.E., Steenbergen C. Amiloride delays the ischaemia-induced rise in cytosolic free calcium. Circ. Res. (1991) 68 1250-1258.
47. McClella K.J., Plosker G.L. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs (1999) 58 143-157.
48. Boucher F.R., Hearse D.J., Opie L.H. Effects of trimetazidine on ischaemic contracture in isolated perfused rat hearts. J. Cardiovasc. Pharmacol. (1994) 24 45-49.
49. El Banani H., Bernard M., Baetz D. et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc. Res. 2000 47 688-696.
50. Fantini E., Demaison L., Sentex E., Grynberg A., Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J. Mol. Cell. Cardiol. (1994) 26 949-958.
51. Harpey C., Clauser P., Labrid C., Freyria J.L., Poirier J.P. Trimetazidine, a cellular anti-ischaemicc agent. Cardiovasc. Drug Rev. (1989) 6 292-312.
52. Kay L., Finelli C., Aussedat J., Guarnieri C., Rossi A. Improvement of long term preservation of the isolated arrested rat heart by trimetazidine: effects of the energy state and mitochondrial function. Am. J. Cardiol. (1995) 76 45B-49B.
53. Lavanchy N., Martin J., Rossi A. Anti-ischaemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch. Int. Pharmacodyn. (1987) 286 97-110, 50.
54. Kantor Pf. Lucien A. Kozak R. Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. (2000) 86 580-588.
55. Lopaschuk G.D. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis (2001) 12(Suppl 1) s8-s11.
56. Kelly D.P., Strauss A.W. Inherited cardiomyopathies. N. Engl. J. Med. (1994) 330 913-919.
57. Corr P.B., Yamada K.A. Selected metabolic alterations in the ischaemic heart and their contributions to arrhythmogenesis. Herz. (1995) 20 156-168.
58. Sentex E., Sergiel J.P., Lucien A., Grynberg A. Is the cytoprotective effect of trimetazidine associated with lipid metabolism? Am. J. Cardio. (1998) 82 18K-24K.
59. Sentex E., Sergiel J.P., Lucien A., Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol. Cell. Biochem. (1997) 175 153-62.
60. Sentex E., Helies-Toussaint C., Rousseau D., Lucien A., Ferrary E., Grynberg A. Influence of trimetazidine on the synthesis of complex lipids in the heart and other target organs. Fund. Clin. Pharmacol. (2001) 15 255-264.
61. Sellier P., Audouin P., Payen B., Corona P., Duong T.C., Ourbak P. Acute effects of trimetazidine evaluated by exercise testing. Eur. J. Clin. Pharmacol. (1987) 33 205-207.
62. 3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Brit. J. Pharmacol. (1998) 123 1385-1394.
63. 3H]-trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance. Brit. J. Pharmacol. (2000) 130 655-663.
64. European Society of Cardiology Task Force. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of cardiology. Eur. Heart J. (1997) 18 394-413.
65. Heidenreich P.A., McDonald K.M., Hastie T. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA (1999) 281 1927-1936.
66. Pepine C.J., Abrams J., Marks R.G. for the TIDES Investigators. Characteristics of a contemporary population with angina pectoris. Am. J. Cardiol. (1994) 74 226-231.
67. Détry J.M. Clinical features of an anti-anginal drug in angina pectoris. Eur. Heart J. (1993) 14 18-24.
68. Détry J.M., Sellier P., Pennaforte S., Cokkinos D., Dargie H., Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br. J. Clin. Pharmacol. (1994) 37 279-288.
69. Levy S, and the group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am. J. Cardiol. (1995) 7612 B-16B.
70. Manchanda S.C., Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart (1997) 78 353-357.
71. Michaelides A.P., Vyssoulis G.P., Bonoris P.E., Psaros T.K., Papadopoulos P.D., Toutouzas P.K. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr. Ther. Res. (1989) 46 565-576.
72. Michaelides A.P., Spiropoulos K., Dimopoulos K., Athanasiades D. Toutouzas P. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin. Drug. Invest. (1997) 13 8-14.
73. Monpère C., Brochier M., Demange J., Ducloux G., Warin J.F. Combination of trimetazidine with nifedipine in effort angina. Cardiovasc. Drug Ther. (1990) 4 824-825.
74. Passeron J. la trimetazidine dans l'angor d'effort stable de l'insuffisant coronarien chronique. Press. Med. (1986) 35 1775-1778.
75. Sellier P. la trimetazidine sur les paramètres ergométriques dans l'angor d'effort. Etude multicentrique contrôlée a double insu contre placebo. Arch. Mal. Coeur. et. Vaiss. (1986) 9 1331-1336.
76. Szwed H., Hradec J., Preda I. Anti-ischaemicc efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies. Coron. Artery. Dis. (2001) 12(Suppl. 1) S25-S28.
77. Szwed H., Sadowski Z., Elikowski W. Combination treatment in stableeffort angina using trimetazidine and metoprolol. Eur. Heart J. (2001) 22 2267-2274.
78. Szwed H., Pachocki R., Domzal-Bochenska M. et al. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse. Medicale. (2000) 29 533-538.
79. Shapiro L.M., Howat A.P., Calter M.N. Left ventricular function in diabetes mellitus. Methodology and prevalence and spectrum of abnormalities. Br. Heart J. (1991) 45 122-128.
80. Stanley W.C., Lopaschuk G.D., McCormack J. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. (1997) 34 25-33.
81. Malmberg K., Ryden L., Hamsten A. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI study group. Eur. Heart J. (1996) 17 1337-1344.
82. Diaz R., Paolasso E.C., Piegas L.S. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation (1998) 98 2227-2234.
83. Szwed H., Pachocki R., Domnzal-Bochenska M. The anti-ischaemicc effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRLMPOLI. Cardiovas. Drug Ther. (1999) 13 215-220.
84. Marzilli M. Management of ischaemicc heart disease in diabetic patients. Is there a role for cardiac metabolic agents? Curr. Med. Res. Opin. (2001) 17 1-6.
85. Stanley W.C., Chandler M.P. Energy metabolism in the failing heart: potential for therapeutic interventions. Heart Failure Reviews (2002) 7 115-130.
86. Lopaschuk G.D., Rebeyka I.M., Allard M.F. Metabolic modulation. A means to mend a broken heart. Circulation (2002) 105 140-142.
87. Brottier A., Barat L., Combe C. Therapeutic value of a cardioprotective agent in patients with severe ischaemicc cardiomyopathy. Eur. Heart J. (1990) 11 207-212.
88. Birand A., Kudaiberdieva G.Z., Batyrnaliev T.A. Effect of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology (1997) 48 413-22.
89. Lu C., Dabrowski P., Fragasso G., Chierchia S. Effects of trimetazidine on ischaemicc left ventricular dysfunction in patients with coronary artery disease. Am. J. Cardiol. (1998) 82 898-901.
90. Belardinelli R., Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemicc cardiomyopathy. Eur. Heart J. (2001) 22 2164-2170.